Study wrapper · #1244
Cognitive signs and symptoms in people with a psychiatric diagnosis on semaglutide: a retrospective cohort study of 13 007 patients in the USA.
Editor's note
A large, well-conducted EHR cohort from an Oxford-affiliated group, using active-comparator designs and the parametric g-formula to reduce obvious biases. Semaglutide beat no-treatment, glipizide, and empagliflozin on a composite cognitive score, though the gap versus sitagliptin did not reach significance — a useful check on overinterpretation. The outcome is a clinician-rated composite from routine notes, not formal neuropsychological testing, and residual confounding by health-seeking behavior is plausible. This adds to a growing cognitive-benefit signal for semaglutide that now needs a randomized trial.
Plain-language abstract
In a US health-records study of 13,007 adults with psychiatric diagnoses, people who started semaglutide had fewer clinician-recorded cognitive problems — such as memory and attention issues — over the following year than people who started other diabetes drugs or no drug at all. The effect was strongest for memory and was most consistent in people with major depression. Because this was an observational study, it can show an association but cannot prove semaglutide caused the improvement.